Reviewer’s report

Title: Discontinuation of hypnotics during cognitive behavioral therapy for insomnia

Version: 3 Date: 9 July 2008

Reviewer: Toshiaki A Furukawa

Reviewer’s report:

Sorry to keep on bothering you but I just cannot let it go once I have noticed some points of improvement.

One essential minor comment:
It is not very good to pretend as if you used the standard CGI from the beginning. It is more honest to write that you used your own version of global impression scale which ranged from X (not ill) to Y (extremely severely ill) or something like that.

One discretionary minor comment:
In Table 3 and elsewhere, it would be more informative for the readers if you wrote out specific p-levels rather than to merely state "NS".

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have received research funds and speaking fees from Asahi Kasei, Astellas, Dai-Nippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Kyowa Hakko, Meiji, Nikken Kagaku, Organon, Otsuka, Pfizer, and Yoshitomi. He was on research advisory board for Pfizer, Janssen, Mochida and Meiji, and is currently on research advisory board for Sekisui Chemicals. He has received royalties from Igaku-Shoin and Seiwa-Shoten. The Japanese Ministry of Education, Science, and Technology and the Japanese Ministry of Health Labor and Welfare have also funded his research.